JP Morgan analyst Daniel Chen assumes Bilibili (NASDAQ:BILI) with a Overweight rating.
JP Morgan Assumes Bilibili at Overweight
JP Morgan analyst Daniel Chen assumes Bilibili (NASDAQ:BILI) with a Overweight rating.
Related Posts
Xenpozyme Approved By FDA As First Disease-Specific Treatment For ASMD
Paris, August 31, 2022. The U.S. Food and Drug Administration (FDA) has approved XenpozymeTM (olipudase alfa-rpcp) for the treatment of non-central nervous system (non-CNS) manifestations of acid sphingomyelinaseParis, August 31, 2022. The U.S.
National Fuel Gas Company Sees EPS $5.10-$5.40 Vs $5.10 Est.
FISCAL 2023 GUIDANCE UPDATE
National Fuel is revising its fiscal 2023 earnings guidance with updated forecast assumptions and projections. The Company is now projecting that earnings, excluding items
Cowen & Co. Maintains Outperform on IHS Holding, Raises Price Target to $29
Cowen & Co. analyst Colby Synesael maintains IHS Holding (NYSE:IHS) with a Outperform and raises the price target from $27 to $29.